Page 2 - நோயாளிகள் அப்பால் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நோயாளிகள் அப்பால். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நோயாளிகள் அப்பால் Today - Breaking & Trending Today

Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF)

Share this article
Share this article
SHANGHAI and HONG KONG, July 5, 2021 /PRNewswire/ Antengene Corporation Limited ( Antengene , SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, recently announced that China s National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for single agent selinexor, a first-in-class orally available Exportin 1 (XPO1) inhibitor, for the treatment of patients with myelofibrosis (MF) in China.
MF is a clonal hematologic neoplasm which can emerge either as primary MF, polycythemia vera (PV) or essential thrombocythemia (ET)
[1]. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the only curative treatment for MF. However, such treatment is difficult to carry out and has a low rate of success. According to the ....

New Zealand , South Korea , Jay Mei , Asia Pacific , S El Jamal , Karyopharm Therapeutics Inc , Antengene Corporation , European Commission , Drug Administration , China National Medical Products Administration , Prnewswire Antengene Corporation Limited , Antengene Corporation Limited , Connective Tissue Oncology Society , Israeli Ministry Of Health , Ministry Of Food , National Comprehensive Cancer Network , Corporation Limited , National Medical Products Administration , Investigational New Drug , Karyopharm Therapeutics , Greater China , Israeli Ministry , Safety Monitoring Board , New Drug Applications , Priority Review , Orphan Drug Designation ,

Antengene Provides an Update on Its Latest Developments

Antengene Provides an Update on Its Latest Developments
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Hong Kong , Calithera Biosciences , Jay Mei , Asia Pacific , Antengene Corporation , Human Research Ethics Committee , Hangzhou Qiantang New Area Administrative Committee , Drug Administration , American Association For Cancer Research , Prnewswire Antengene Corporation Limited , Antengene Corporation Limited , National Medical Products Administration , Chinese Society Of Clinical Oncology , Corporation Limited , Clinical Oncology , Cancer Research , Mainland China , Investigational New Drug , Treating Patients Beyond Borders , Asia Pacific Region , Patients Beyond , ஒன்றுபட்டது மாநிலங்களில் , ஹாங் காங் , ஜெய் மெய் , ஆசியா பெஸிஃபிக் ,

Antengene Announces Publication of Abstract on XPO1 Inhibitor Selinexor in Relapsed or Refractory Multiple Myeloma at ASCO 2021 and EHA 2021

Antengene Announces Publication of Abstract on XPO1 Inhibitor Selinexor in Relapsed or Refractory Multiple Myeloma at ASCO 2021 and EHA 2021
-Results from the MARCH trial showed an ORR of 33.3% in triple-class-exposed RRMM patients with the Sd regimen, and 44.4% in patients who previously received CAR-T therapies-
-Selinexor is currently the only commercially available XPO1 inhibitor-
News provided by
Share this article
Share this article
SHANGHAI and HONG KONG, June 3, 2021 /PRNewswire/ Antengene Corporation Limited ( Antengene , SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, announced that the results from the Phase II MARCH trial of selinexor plus low dose dexamethasone (the Sd regimen) for the treatment of Chinese patients with relapsed or refractory multiple myeloma (RRMM) are published at the 20 ....

United States , Asia Pacific , Antengene Corporation , American Society Of Clinical Oncology , European Hematology Association , Drug Administration , Prnewswire Antengene Corporation Limited , Antengene Corporation Limited , Virtual Congress , National Comprehensive Cancer Network , Chinese Society Of Clinical Oncology , Corporation Limited , Clinical Oncology , Annual Meeting , Hematology Association , Chinese Society , Asia Pacific Region , Patients Beyond , ஒன்றுபட்டது மாநிலங்களில் , ஆசியா பெஸிஃபிக் , அமெரிக்கன் சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல் , ஐரோப்பிய ஹீமாட்டாலஜி சங்கம் , மெய்நிகர் காங்கிரஸ் , தேசிய விரிவான புற்றுநோய் வலைப்பின்னல் , சீன சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல் , நிறுவனம் வரையறுக்கப்பட்டவை ,

Antengene Announces Abstracts on Twelve Clinical Studies of Selinexor Selected by EHA 2021

/PRNewswire/ Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing. ....

United States , Ciltacabtagene Autoleucel , Asia Pacific , Antengene Corporation , Prnewswire Antengene Corporation Limited , European Hematology Association , Antengene Corporation Limited , Corporation Limited , Annual Congress , Asia Pacific Region , Patients Beyond , ஒன்றுபட்டது மாநிலங்களில் , ஆசியா பெஸிஃபிக் , ஐரோப்பிய ஹீமாட்டாலஜி சங்கம் , நிறுவனம் வரையறுக்கப்பட்டவை , ஆண்டு காங்கிரஸ் , ஆசியா பெஸிஃபிக் பகுதி , நோயாளிகள் அப்பால் ,

Antengene Announces Fifteen Clinical Studies and Results of Selinexor to be Presented at ASCO 2021

/PRNewswire/ Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing. ....

United States , Asia Pacific , Antengene Corporation , American Society Of Clinical Oncology , Prnewswire Antengene Corporation Limited , Antengene Corporation Limited , Corporation Limited , Clinical Oncology , Annual Meeting , Asia Pacific Region , Patients Beyond , ஒன்றுபட்டது மாநிலங்களில் , ஆசியா பெஸிஃபிக் , அமெரிக்கன் சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல் , நிறுவனம் வரையறுக்கப்பட்டவை , மருத்துவ புற்றுநோயியல் , ஆண்டு சந்தித்தல் , ஆசியா பெஸிஃபிக் பகுதி , நோயாளிகள் அப்பால் ,